| Abstrak/Abstract |
Vesnarinoneis known to have multifunctional biological activities including cell growth and metastases suppression of various types of human cancers. Vesnarinone has been widely used for the treatment of chronic heart failure because it’s activity as an oral inotropic agent. In the present study, the antitumor activity of vesnarinone against oral malignant Burkitt lymphoma (Raji) cells through analysis of proliferative barriers, migratory chemotactic suppression and cell apoptosisinduction was examined. The pure laboratory experimental with post-test design only control group design was performed in this study. Raji cells were cultured until the 5th passage. Raji cellswere incubated with vesnarinone doses of 0, 1.25x10-2, 2.5x10-2 and 5x10-2 M, and IC50 carboplatin (3.1x 10-6 M) as positive control. After 24 and 48 hours incubation, cells were harvested in the Petry dish. Cell growth inhibition test or MTT assay was carried-out by ELISA reader. Cell migratory chemotaxis analysis was delivered by Boyden chamber kit, and cell apoptosis assay was detectedby double staining Acridine orange-Ethidium bromide (AO-EB).The results revealed quinolinone derivate-vesnarinone was significantly inhibited the cell proliferation and migratory chemotactic activity of an oral malignant Burkitt’slymphoma cells characterized by increased in the number of cells apoptosis (P<0.001). Elevated their inhibition and induction of cell apoptosis was proportional to an increase in vesnarinone doses.In conclusions, quinolinone derivatevesnarinone had a strong antitumor activity against oral malignant Burkitt lymphoma cells. Experimental |
